REGULATORY
Chuikyo Leaning toward Continuing Innovation Premium for On-Patent Drugs
The Central Social Insurance Medical Council (Chuikyo) appears to be moving towards continuing the so-called price maintenance premium for on-patent medicines in its current form beyond April, as demanded by pharmaceutical industry groups. Chuikyo’s drug pricing subcommittee discussed the premium,…
To read the full story
Related Article
REGULATORY
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
- Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
- US Opens Probe into German Drug Pricing Policies; Could Japan Be Next?
June 24, 2026
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…





